Chemotherapy options in elderly and frail patients with metastatic colorectal cancer.
作者信息
Saif Muhammad Wasif
机构信息
Research funding from Roche, Genentech.
出版信息
Ann Gastroenterol. 2012;25(3):274-275.
Abstract
摘要
相似文献
1
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer.老年及体弱转移性结直肠癌患者的化疗选择
Ann Gastroenterol. 2012;25(3):274-275.
2
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.单药帕尼单抗治疗老年体弱的晚期RAS和BRAF野生型结直肠癌患者：挑战药品标签以点亮新希望
Oncologist. 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.2015-0171. Epub 2015 Oct 7.
3
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.老年和虚弱型转移性结直肠癌（MRC FOCUS2）患者的化疗选择：一项开放标签、随机分组的析因试验。
Lancet. 2011 May 21;377(9779):1749-59. doi: 10.1016/S0140-6736(11)60399-1. Epub 2011 May 11.
4
The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO).老年干预对接受化疗的老年体弱结直肠癌患者的影响：一项随机试验（GERICO）
BMC Cancer. 2017 Jun 28;17(1):448. doi: 10.1186/s12885-017-3445-8.
5
Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.卡培他滨与贝伐单抗治疗的转移性结直肠癌体弱和/或老年患者的身体功能和生活质量：一项探索性分析。
J Geriatr Oncol. 2014 Oct 1;5(4):368-75. doi: 10.1016/j.jgo.2014.05.002. Epub 2014 Jul 4.
6
Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGSG 1602.帕尼单抗单药治疗化疗初治、虚弱或老年不可切除 RAS 野生型结直肠癌患者的 II 期研究：OGSG1602。
Oncologist. 2021 Jan;26(1):17-e47. doi: 10.1002/ONCO.13523. Epub 2020 Sep 28.
7
Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer.S-1 单药治疗老年或虚弱转移性结直肠癌患者的 II 期临床试验。
Invest New Drugs. 2011 Oct;29(5):1073-80. doi: 10.1007/s10637-010-9418-2. Epub 2010 Mar 21.
8
Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.回顾性研究：一线化疗联合抗 VEGF 抗体与氟嘧啶类药物治疗不能切除或转移性结直肠癌的虚弱患者。
Digestion. 2013;87(1):59-64. doi: 10.1159/000343943. Epub 2013 Jan 21.
9
Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.纳入老年或虚弱患者的针对转移性结直肠癌的靶向治疗的随机对照试验：系统评价。
J Geriatr Oncol. 2018 Jan;9(1):15-23. doi: 10.1016/j.jgo.2017.08.001. Epub 2017 Aug 24.
10
Chemotherapy for operable and advanced colorectal cancer.可手术及晚期结直肠癌的化疗
Cancer Treat Rev. 2009 Oct;35(6):509-16. doi: 10.1016/j.ctrv.2009.04.003. Epub 2009 May 29.
引用本文的文献
1
Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study.与瑞戈非尼一线治疗转移性结直肠癌患者获益相关的生物标志物：REFRAME分子研究
Cancers (Basel). 2021 Apr 4;13(7):1710. doi: 10.3390/cancers13071710.
本文引用的文献
1
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.序贯与联合化疗治疗晚期结直肠癌（FFCD 2000-05）：一项开放标签、随机、3 期临床试验。
Lancet Oncol. 2011 Oct;12(11):1032-44. doi: 10.1016/S1470-2045(11)70199-1. Epub 2011 Sep 6.
2
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.老年和虚弱型转移性结直肠癌（MRC FOCUS2）患者的化疗选择：一项开放标签、随机分组的析因试验。
Lancet. 2011 May 21;377(9779):1749-59. doi: 10.1016/S0140-6736(11)60399-1. Epub 2011 May 11.
3
Chemotherapy options and outcomes in older adult patients with colorectal cancer.老年结直肠癌患者的化疗选择与治疗结果
Crit Rev Oncol Hematol. 2009 Nov;72(2):155-69. doi: 10.1016/j.critrevonc.2009.02.006. Epub 2009 Apr 7.
4
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.晚期预后不良的结直肠癌患者序贯和联合化疗的不同策略（MRC FOCUS）：一项随机对照试验
Lancet. 2007 Jul 14;370(9582):143-152. doi: 10.1016/S0140-6736(07)61087-3.
5
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.卡培他滨、伊立替康和奥沙利铂序贯与联合化疗用于晚期结直肠癌（CAIRO）：一项III期随机对照试验
Lancet. 2007 Jul 14;370(9582):135-142. doi: 10.1016/S0140-6736(07)61086-1.
6
Tolerance to chemotherapy in elderly patients with cancer.老年癌症患者对化疗的耐受性
Cancer Control. 2007 Jan;14(1):44-56. doi: 10.1177/107327480701400106.
7
Physiologic aspects of aging: impact on cancer management and decision making, part II.衰老的生理方面：对癌症管理和决策的影响，第二部分。
Cancer J. 2005 Nov-Dec;11(6):461-73. doi: 10.1097/00130404-200511000-00005.
8
Physiologic aspects of aging: impact on cancer management and decision making, part I.衰老的生理方面：对癌症管理和决策的影响，第一部分
Cancer J. 2005 Nov-Dec;11(6):449-60. doi: 10.1097/00130404-200511000-00004.
9
Population aging and cancer: a cross-national concern.人口老龄化与癌症：一个跨国关注的问题。
Cancer J. 2005 Nov-Dec;11(6):437-41. doi: 10.1097/00130404-200511000-00002.
10
The frailty syndrome: a critical issue in geriatric oncology.衰弱综合征：老年肿瘤学中的一个关键问题。
Crit Rev Oncol Hematol. 2003 May;46(2):127-37. doi: 10.1016/s1040-8428(02)00177-4.
Zotero 插件